Artelo Biosciences, Inc.
ARTL
$5.98
-$0.21-3.39%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 61.88% | 71.35% | 45.35% | 39.26% | 10.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.06% | 18.35% | 12.82% | 30.35% | -3.82% |
| Operating Income | -5.06% | -18.35% | -12.82% | -30.35% | 3.82% |
| Income Before Tax | -20.64% | -38.60% | -31.07% | -36.95% | -0.62% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.64% | -38.60% | -31.07% | -36.95% | -0.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.64% | -38.60% | -31.07% | -36.95% | -0.62% |
| EBIT | -5.06% | -18.35% | -12.82% | -30.35% | 3.82% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 59.50% | 27.10% | 13.42% | -21.53% | 5.31% |
| Normalized Basic EPS | 62.79% | 31.51% | 18.83% | -16.59% | 8.95% |
| EPS Diluted | 59.50% | 27.10% | 13.42% | -21.53% | 5.31% |
| Normalized Diluted EPS | 62.79% | 31.51% | 18.83% | -16.59% | 8.95% |
| Average Basic Shares Outstanding | 493.67% | 156.50% | 83.79% | 15.36% | 6.02% |
| Average Diluted Shares Outstanding | 493.67% | 156.50% | 83.79% | 15.36% | 6.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |